PAVmed Selling And Marketing Expenses from 2010 to 2024

PAVMZ Stock  USD 0.01  0.0001  0.66%   
PAVmed Series Selling And Marketing Expenses yearly trend continues to be fairly stable with very little volatility. Selling And Marketing Expenses will likely drop to about 13.4 M in 2024. During the period from 2010 to 2024, PAVmed Series Selling And Marketing Expenses regression line of annual values had r-squared of  0.53 and arithmetic mean of  5,989,058. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2010-12-31
Previous Quarter
17.6 M
Current Value
13.4 M
Quarterly Volatility
5.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check PAVmed Series financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed Series' main balance sheet or income statement drivers, such as Interest Expense of 559.5 K, Selling General Administrative of 32.5 M or Other Operating Expenses of 74.8 M, as well as many indicators such as Price To Sales Ratio of 11.54, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Series Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Latest PAVmed Series' Selling And Marketing Expenses Growth Pattern

Below is the plot of the Selling And Marketing Expenses of PAVmed Series Z over the last few years. It is PAVmed Series' Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed Series' overall financial position and show how it may be relating to other accounts over time.
Selling And Marketing Expenses10 Years Trend
Slightly volatile
   Selling And Marketing Expenses   
       Timeline  

PAVmed Selling And Marketing Expenses Regression Statistics

Arithmetic Mean5,989,058
Geometric Mean4,302,603
Coefficient Of Variation98.53
Mean Deviation4,693,419
Median2,789,000
Standard Deviation5,901,044
Sample Variance34.8T
Range16.5M
R-Value0.73
Mean Square Error17.5T
R-Squared0.53
Significance0
Slope963,700
Total Sum of Squares487.5T

PAVmed Selling And Marketing Expenses History

202413.4 M
202317.6 M
202219.3 M
20218.9 M

About PAVmed Series Financial Statements

PAVmed Series investors use historical fundamental indicators, such as PAVmed Series' Selling And Marketing Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in PAVmed Series. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling And Marketing Expenses17.6 M13.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.